SCHEMBL925636

SCHEMBL925636

NC(=O)CCc1ccc(O)c(O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 3/20 0.62
APP P05067 2/20 0.59
CYP19A1 P11511 1/20 0.59
TYR P14679 1/20 0.59
KDM4E B2RXH2 5/20 0.59
MAPT P10636 5/20 0.59
TDP1 Q9NUW8 3/20 0.59
ALDH1A1 P00352 3/20 0.59
HIF1A Q16665 3/20 0.59
HSD17B10 Q99714 3/20 0.59
ALOX15 P16050 2/20 0.59
ADRA2A P08913 2/20 0.59
DRD2 P14416 2/20 0.59
DRD1 P21728 2/20 0.59
DRD4 P21917 2/20 0.59
DRD5 P21918 2/20 0.59
SLC6A2 P23975 2/20 0.59
MAPK1 P28482 2/20 0.59
DRD3 P35462 2/20 0.59
RECQL P46063 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30986806 1.00 IAPP (0.62) IAPPAPPCYP19A1TYRKDM4E
Hydrochloric Acid SCHEMBL10340417 0.98 IAPP (0.61) IAPPAPPCYP19A1TYRKDM4E
SCHEMBL29381000 0.90 ALOX15 (0.67) IAPPAPPKDM4EMAPTTDP1
SCHEMBL6346995 0.90 ALOX15 (0.67) IAPPAPPKDM4EMAPTTDP1
SCHEMBL6340368 0.87 ALOX15 (0.68) IAPPKDM4EMAPTTDP1ALDH1A1
SCHEMBL24854636 0.86 CNR1 (0.55) IAPPAPPCYP19A1TYRKDM4E
SCHEMBL28165571 0.83 IAPP (0.82) IAPPAPPCYP19A1TYRKDM4E
SCHEMBL28022655 0.83 CA2 (0.56) IAPPAPPCYP19A1TYRHSD17B10
SCHEMBL23476677 0.83 HIF1A (0.49) IAPPAPPCYP19A1TYRKDM4E
SCHEMBL28659512 0.83 ESR1 (0.55) IAPPAPPCYP19A1TYRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0644772-A4 OPIOID PEPTIDES. BIOMEASURE INC (US) 1997-01-29 EP claimed
EP-0644772-A1 OPIOID PEPTIDES BIOMEASURE, INC. (US) 1995-03-29 EP claimed
WO-1994011018-A1 OPIOID PEPTIDES BIOMEASURE, INC. (US) 1994-05-26 WO claimed
JP-2053767-A None JP disclosed
JP-5032646-A None JP disclosed
EP-4192824-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE Cornell University (US) 2023-06-14 EP disclosed
WO-2022031772-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE CORNELL UNIVERSITY (US) 2022-02-10 WO disclosed
CN-109310649-B Dihydrochalcone derivatives affecting inflammatory states 西姆莱斯有限公司 2021-06-29 CN disclosed
US-10758468-B2 Solubilizer for cosmetic preparations SYMRISE AG (DE) 2020-09-01 US disclosed
CN-108495617-A Including the pharmaceutical composition of levodopa amide and its purposes 纽罗德姆有限公司 2018-09-04 CN disclosed
US-20170312384-A9 MULTIBRANCHED BIOADHESIVE COMPOUNDS AND SYNTHETIC METHODS THEREFOR DSM IP ASSETS B.V. (NL) 2017-11-02 US disclosed
US-20030171617-A1 3,4-Dihydroxymandelic acid alkylamides and use thereof HAARMANN & REIMER GMBH (DE) 2003-09-11 US disclosed
US-20030139470-A1 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants HAARMANN & REIMER GMBH (DE) 2003-07-24 US disclosed
US-20030072725-A1 Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles HAARMANN & REIMER GMBH (DE) 2003-04-17 US disclosed
US-20030049287-A1 Catechol oximes and their use in cosmetic and dermatological preparations HAARMANN & REIMER GMBH (DE) 2003-03-13 US disclosed
JP-H0532646-A DIHYDROCAFFEIC ACID AMIDE DERIVATIVE AND USE THEREOF FOR MEDICINE MITSUI TOATSU CHEM INC 1993-02-09 JP disclosed
EP-0495998-A1 DIHYDROCAFFEIC ACID AMIDE DERIVATIVE AND APPLICATION THEREOF AS MEDICINE MITSUI TOATSU CHEMICALS, Inc. (JP) 1992-07-29 EP disclosed
WO-1992002490-A1 DIHYDROCAFFEIC ACID AMIDE DERIVATIVE AND APPLICATION THEREOF AS MEDICINE MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-02-20 WO disclosed
JP-H0253767-A DIHYDROCAFFEIC ACID AMIDE COMPOUND AND REMEDY CONAINING THE SAME AMIDE AS ACTIVE INGREDIENT MITSUI TOATSU CHEM INC 1990-02-22 JP disclosed
US-4448730-A ANTITUMOR AGENTS RIET BARTHOLOMEUS VAN T 1984-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10758468-B2 Solubilizer for cosmetic preparations SRPK3, SRPK1, SYMPK IAPP 3938/4885APP 3387/4885CYP19A1 1923/4885
US-20030171617-A1 3,4-Dihydroxymandelic acid alkylamides and use thereof HNMT, HTR2A, HTR2C IAPP 1464/4885APP 2858/4885CYP19A1 1197/4885
US-20030049287-A1 Catechol oximes and their use in cosmetic and dermatological preparations TYR, LPO, COMT IAPP 4690/4885APP 3260/4885CYP19A1 47/4885
US-20030139470-A1 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants TYR, HAAO, TH IAPP 1938/4885APP 1138/4885CYP19A1 140/4885
US-20030072725-A1 Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles TYR, MITF, HDAC1 IAPP 4837/4885APP 4317/4885CYP19A1 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.